Upgrade to SI Premium - Free Trial

Needham & Company Reiterates Hold on Neurocrine (NBIX), Calls Earnings Uneventful, Does Not Expect Big Move in Stock

February 11, 2022 8:19 AM
Needham & Company analyst Ami Fadia reiterated a Hold rating on Neurocrine Bio. (NASDAQ: NBIX) following the company's most recent ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Trader Talk

Next Articles